Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
240 studies found for:    AKT1
Show Display Options
Rank Status Study
1 Recruiting Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
Conditions: Advanced Solid Malignancy;   Safety and Tolerability;   Pharmacokinetics;   Pharmacodynamics;   Tumour Response;   Advanced or Metastatic Breast Cancer;   Ovarian Cancer;   Cervical Cancer;   Endometrial Cancer;   PIK3CA;   AKT1;   ER+;   HER2+
Intervention: Drug: AZD5363
2 Recruiting Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients
Condition: Neoplasms
Intervention: Drug: BAY1125976
3 Completed
Has Results
Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)
Conditions: Glioblastoma;   Gliosarcoma
Intervention: Drug: Bevacizumab and Erlotinib
4 Recruiting NGS Genome Analysis in Personalisation of Lung Cancer Treatment
Condition: Lung Cancer
Intervention: Other: blood sample, biopsy
5 Enrolling by invitation A Neurobiological Study on Heterogeneity of Schizophrenia: Genetic Variations and Neurobiological Differentiations
Condition: Schizophrenia
Intervention:
6 Enrolling by invitation Impact of Chronic Circadian Disruption vs. Chronic Sleep Restriction on Metabolism
Conditions: Aging;   Sleep Restriction;   Circadian Disruption
Interventions: Behavioral: Circadian Disruption;   Behavioral: Sleep Restriction;   Behavioral: Control
7 Completed A Study of MK-8033 in Patients With Advanced Solid Tumors (MK-8033-001)
Condition: Advanced Cancer
Interventions: Drug: Comparator: MK-8033;   Drug: Comparator: MK-8033 +/- omeprazole
8 Active, not recruiting Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer
Condition: Malignant Neoplasm
Interventions: Drug: cixutumumab;   Drug: temsirolimus;   Other: laboratory biomarker analysis;   Other: pharmacological study
9 Recruiting Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: trametinib;   Drug: Akt inhibitor GSK2141795;   Other: laboratory biomarker analysis
10 Recruiting Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
Conditions: Mucinous Adenocarcinoma of the Colon;   Mucinous Adenocarcinoma of the Rectum;   Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Signet Ring Adenocarcinoma of the Colon;   Signet Ring Adenocarcinoma of the Rectum;   Stage IIIA Colon Cancer;   Stage IIIA Rectal Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Rectal Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Rectal Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer
Interventions: Drug: Akt inhibitor MK2206;   Other: laboratory biomarker analysis;   Other: pharmacological study
11 Recruiting Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast Cancer
Conditions: Stage 0 Breast Carcinoma;   Breast Neoplasms;   Stage I Breast Carcinoma;   Stage II Breast Carcinoma;   Stage III Breast Carcinoma
Interventions: Drug: Metformin;   Drug: Omega-3 fatty acids
12 Recruiting Efficacy and Safety of the Mammalian Target of Rapamycin (mTor Rapamycin) Inhibitor in Vascular Malformations
Condition: Cardiovascular Abnormalities
Intervention: Drug: Sirolimus
13 Recruiting Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer
Conditions: Endometrial Adenocarcinoma;   Endometrial Clear Cell Carcinoma;   Endometrial Papillary Serous Carcinoma;   Recurrent Endometrial Carcinoma
Interventions: Drug: trametinib;   Drug: Akt inhibitor GSK2141795;   Other: laboratory biomarker analysis
14 Active, not recruiting Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: B-cell Chronic Lymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia
Interventions: Drug: Akt inhibitor MK2206;   Biological: rituximab;   Drug: bendamustine hydrochloride;   Other: laboratory biomarker analysis
15 Active, not recruiting A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer
Conditions: Ovarian Sarcoma;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer
Interventions: Drug: Akt inhibitor MK2206;   Other: laboratory biomarker analysis
16 Active, not recruiting Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Drug: sorafenib tosylate;   Drug: temsirolimus;   Biological: bevacizumab;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: dynamic contrast-enhanced magnetic resonance imaging
17 Active, not recruiting A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia
Conditions: Acute Lymphoblastic Leukemia;   Leukemia, Myelocytic, Acute;   Chronic Myelogenous Leukemia With Crisis of Blast Cells
Intervention: Drug: BEZ235
18 Recruiting Molecular Phenotype Changes and Personalized Treatment for CRPC
Condition: Hormone Refractory Prostate Cancer
Interventions: Drug: Docetaxel & Prednisone;   Drug: DP & Targeted drugs;   Drug: cisplatin & Etoposide;   Drug: EP & Targeted drugs
19 Recruiting A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma
Condition: Renal Cell Carcinoma
Intervention: Drug: RAD001
20 Unknown  The Roles of Neutrophil Elastase in Lung Cancer
Conditions: Lung Cancer;   Chronic Obstructive Pulmonary Diseases
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years